PRELUDE THERAPEUTICS INC Comprehensive Income
PRELUDE THERAPEUTICS INC (PRLD) reported Comprehensive Income of -$14.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$14.11M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$10.43M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$16.45M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$19.72M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$99.53M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$127.36M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$119.92M.
- PRELUDE THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$116.42M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.11M 10-Q · filed 2026-08-11 | -$24.54M 10-Q · filed 2026-08-11 | -$40.99M derived: sum of 3 quarters · filed 2026-08-11 | -$60.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$10.43M 10-Q · filed 2026-05-12 | -$26.89M derived: sum of 2 quarters · filed 2026-05-12 | -$46.61M derived: sum of 3 quarters · filed 2026-05-12 | -$77.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$36.17M derived: sum of 2 quarters · filed 2026-03-10 | -$67.42M derived: sum of 3 quarters · filed 2026-08-11 | -$99.53M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$19.72M 10-Q · filed 2025-11-12 | -$50.97M derived: sum of 2 quarters · filed 2026-08-11 | -$83.07M 10-Q · filed 2025-11-12 | -$111.94M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$31.24M 10-Q · filed 2026-08-11 | -$63.35M 10-Q · filed 2026-08-11 | -$92.22M derived: sum of 3 quarters · filed 2026-08-11 | -$124.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$32.11M 10-Q · filed 2026-05-12 | -$60.97M derived: sum of 2 quarters · filed 2026-05-12 | -$92.78M derived: sum of 3 quarters · filed 2026-05-12 | -$127.58M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$28.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$60.68M derived: sum of 2 quarters · filed 2026-03-10 | -$95.47M derived: sum of 3 quarters · filed 2026-03-10 | -$127.36M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$31.81M 10-Q · filed 2025-11-12 | -$66.61M derived: sum of 2 quarters · filed 2025-11-12 | -$98.50M 10-Q · filed 2025-11-12 | -$130.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$34.80M 10-Q · filed 2025-08-14 | -$66.68M 10-Q · filed 2025-08-14 | -$98.93M derived: sum of 3 quarters · filed 2025-08-14 | -$129.43M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$31.89M 10-Q · filed 2025-05-06 | -$64.14M derived: sum of 2 quarters · filed 2025-05-06 | -$94.64M derived: sum of 3 quarters · filed 2025-05-06 | -$125.38M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$32.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$62.75M derived: sum of 2 quarters · filed 2025-03-10 | -$93.49M derived: sum of 3 quarters · filed 2025-03-10 | -$119.92M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$30.50M 10-Q · filed 2024-11-06 | -$61.25M derived: sum of 2 quarters · filed 2024-11-06 | -$87.67M 10-Q · filed 2024-11-06 | -$115.64M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$30.74M 10-Q · filed 2024-08-12 | -$57.17M 10-Q · filed 2024-08-12 | -$85.14M derived: sum of 3 quarters · filed 2024-08-12 | -$115.17M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$26.42M 10-Q · filed 2024-05-07 | -$54.39M derived: sum of 2 quarters · filed 2024-05-07 | -$84.42M derived: sum of 3 quarters · filed 2024-05-07 | -$111.78M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$27.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$58.00M derived: sum of 2 quarters · filed 2024-02-15 | -$85.35M derived: sum of 3 quarters · filed 2024-02-15 | -$116.42M 10-K · filed 2024-02-15 |
| 2022-09-30 | -$30.03M 10-Q · filed 2023-11-01 | -$57.38M derived: sum of 2 quarters · filed 2023-11-01 | -$88.45M 10-Q · filed 2023-11-01 | -$121.83M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$27.36M 10-Q · filed 2023-08-03 | -$58.42M 10-Q · filed 2023-08-03 | -$91.80M derived: sum of 3 quarters · filed 2023-08-03 | -$122.66M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$31.07M 10-Q · filed 2023-05-08 | -$64.44M derived: sum of 2 quarters · filed 2023-05-08 | -$95.31M derived: sum of 3 quarters · filed 2023-05-08 | -$122.17M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$33.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$64.24M derived: sum of 2 quarters · filed 2023-03-15 | -$91.11M derived: sum of 3 quarters · filed 2023-03-15 | -$112.41M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$30.86M 10-Q · filed 2022-11-14 | -$57.73M derived: sum of 2 quarters · filed 2022-11-14 | -$79.03M 10-Q · filed 2022-11-14 | -$98.28M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$26.86M 10-Q · filed 2022-08-09 | -$48.16M 10-Q · filed 2022-08-09 | -$67.42M derived: sum of 3 quarters · filed 2022-08-09 | -$84.17M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$21.30M 10-Q · filed 2022-05-10 | -$40.55M derived: sum of 2 quarters · filed 2022-05-10 | -$57.31M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$19.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$36.01M derived: sum of 2 quarters · filed 2022-03-17 | -$56.93M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$16.76M 10-Q · filed 2021-11-12 | -$37.68M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |